LOS ANGELES--(BUSINESS WIRE)--Cynvenio Biosystems, Inc. today announced the launch of a new commercial program granting early access to its LiquidBiopsy Rare Cell Isolation Platform. The LiquidBiopsy system automates the identification and enrichment of rare tumor cells from standard patient blood draws.
This program makes it possible for cancer research labs to have direct, on-site access to genomic material from highly purified cell populations for analysis with a variety of downstream molecular technologies. With the ability to detect as few as 1 target cell per mL (billion), the LiquidBiopsy platform delivers the ultra-high sample purity needed for next-gen sequencing, PCR, expression analysis as well as traditional FISH and IHC.
Hey, check out all the research scientist jobs. Post your resume today!
